Although currently only FDA approved for identifying EGFR mutations in NSCLC, liquid biopsies promise to provide a non-invasive means of analyzing inter- and intra-tumoral heterogeneity, even detecting de novo mutations as disease progresses. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.